A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Durvalumab
DRUG: Danvatirsen
DRUG: Oleclumab
DRUG: MEDI5752
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Nab-paclitaxel
DRUG: AZD2936

Sponsor

AstraZeneca